Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Colorectal Disease
Published in: International Journal of Colorectal Disease 8/2018

Open Access 01-08-2018 | Review

Meta-analysis of the prognostic value of CpG island methylator phenotype in rectal cancer

Authors: R. F. Kokelaar, H. Jones, J. Beynon, M. E. Evans, D. A. Harris

Published in: International Journal of Colorectal Disease | Issue 8/2018

Login to get access

Abstract

Purpose

The pathological and prognostic importance of CpG island methylator phenotype (CIMP) in rectal cancer, as a sub-population of colorectal cancer, is unknown. A meta-analysis was preformed to estimate the prognostic significance of CIMP in rectal cancer.

Methods

A systematic search was performed of PubMed, Embase, MEDLINE, PubMed Central, and Cochrane electronic databases for articles pertaining to CIMP and rectal cancer. Articles were analysed and data extracted according to PRISMA standards.

Results

Six studies including 1529 patients were included in the analysis. Following dichotomisation, the prevalence of CIMP-positive tumours was 10 to 57%, with a median of 12.5%. Meta-analysis demonstrated the pooled odds ratio for all-cause death for CIMP-positive tumours vs CIMP-negative tumours was 1.24 (95% CI 0.88–1.74). Z test for overall effect was 1.21 (p = 0.23). Heterogeneity between the studies was low (X2 5.96, df 5, p = 0.31, I2 = 16%). A total of 15 different loci were used for assessing CIMP across the studies, with a median of 6.5 loci (range 5–8).

Conclusions

No significant association between CIMP and poor outcomes in rectal cancer was demonstrated. There was a high degree of heterogeneity in CIMP assessment methodologies and in study populations. Rectal cancer datasets were frequently not extractable from larger colorectal cohorts, limiting analysis.
Literature
1.
2.
3.
Brown KGM, Solomon MJ (2018) Progress and future direction in the management of advanced colorectal cancer. Br J Surg 105(6):615–617CrossRefPubMed
4.
Habr-Gama A, São Julião GP, Vailati BB, Castro I, Raffaele D (2017) Management of the complete clinical response. Clin Colon Rectal Surg 30(5):387–394CrossRefPubMed
5.
Perez RO, Habr-Gama A, Lynn PB, São Julião GP, Bianchi R, Proscurshim I, Gama-Rodrigues J (2013) Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution. Dis Colon Rectum 56(1):6–13CrossRefPubMed
6.
Kong JC et al (2017) Outcome and salvage surgery following “watch and wait” for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum 60(3):335–345PubMed
7.
Torok JA, Palta M, Willett CG, Czito BG (2016) Nonoperative management of rectal cancer. Cancer 122(1):34–41CrossRefPubMed
8.
Dayde D, Tanaka I, Jain R, Tai M, Taguchi A (2017) Predictive and prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer. Int J Mol Sci 18(3):573CrossRefPubMedCentral
9.
Karagkounis G, Kalady MF (2017) Molecular biology: are we getting any closer to providing clinically useful information? Clin Colon Rectal Surg 30(5):415–422CrossRefPubMed
10.
Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J (2017) Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 17(2):79–92CrossRefPubMed
11.
12.
Williamson JS, Harris DA, Beynon J, Jenkins GJS (2015) Review of the development of DNA methylation as a marker of response to neoadjuvant therapy and outcomes in rectal cancer. Clin Epigenetics 7(1):70CrossRefPubMedPubMedCentral
13.
14.
Bae JM, Kim JH, Kang GH (2016) Molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway. Arch Pathol Lab Med 140(5):406–412CrossRefPubMed
15.
Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S (2012) Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61(6):847–854CrossRefPubMedPubMedCentral
16.
Bae JM, Kim JH, Cho NY, Kim TY, Kang GH (2013) Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer 109(4):1004–1012CrossRefPubMedPubMedCentral
17.
Jo P, Jung K, Grade M, Conradi LC, Wolff HA, Kitz J, Becker H, Rüschoff J, Hartmann A, Beissbarth T, Müller-Dornieden A, Ghadimi M, Schneider-Stock R, Gaedcke J (2012) CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Surgery 151(4):564–570CrossRefPubMed
18.
Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, Yu T, Easwaran H, Baylin S, van Engeland M, Ahuja N (2014) Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol 25(12):2314–2327CrossRefPubMedPubMedCentral
19.
Draht MXG, Goudkade D, Koch A, Grabsch HI, Weijenberg MP, van Engeland M, Melotte V, Smits KM (2018) Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review. Clin Epigenetics 10:35CrossRefPubMedPubMedCentral
20.
21.
Powell A et al (2018) Meta-analysis of the prognostic value of CpG island methylator phenotype in gastric cancer. Br J Surg 105(2):e61–e68CrossRefPubMed
22.
Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605CrossRefPubMed
23.
Moher D, Liberati A, Tetzlaff J, Altman DG, for the PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj 339:b2535CrossRefPubMedPubMedCentral
24.
Higgins JPT et al (2003) Measuring inconsistency in meta-analyses. Br Med J 327(7414):557–560CrossRef
25.
Samowitz WS, Curtin K, Wolff RK, Tripp SR, Caan BJ, Slattery ML (2009) Microsatellite instability and survival in rectal cancer. Cancer Causes Control 20(9):1763–1768CrossRefPubMedPubMedCentral
26.
Williamson JS, Jones HG, Williams N, Griffiths AP, Jenkins G, Beynon J, Harris DA (2017) Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: influence of the CpG island methylator phenotype. World J Gastrointest Oncol 9(5):209–217CrossRefPubMedPubMedCentral
27.
Kim CH, Huh JW, Kim HR, Kim YJ (2017) CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: a prospective cohort study. J Gastroenterol Hepatol 32(8):1469–1474CrossRefPubMed
28.
29.
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740CrossRefPubMed
30.
Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38(7):787–793CrossRefPubMed
31.
Jia M, Gao X, Zhang Y, Hoffmeister M, Brenner H (2016) Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics 8:25CrossRefPubMedPubMedCentral
32.
Kohonen-Corish MR et al (2014) KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. Int J Cancer 134(12):2820–2828CrossRefPubMed
33.
Xing X, Cai W, Shi H, Wang Y, Li M, Jiao J, Chen M (2013) The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis. Br J Cancer 108(12):2542–2548CrossRefPubMedPubMedCentral
34.
Yi JM, Dhir M, van Neste L, Downing SR, Jeschke J, Glockner SC, de Freitas Calmon M, Hooker CM, Funes JM, Boshoff C, Smits KM, van Engeland M, Weijenberg MP, Iacobuzio-Donahue CA, Herman JG, Schuebel KE, Baylin SB, Ahuja N (2011) Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res 17(6):1535–1545CrossRefPubMedPubMedCentral
35.
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JPJ (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96(15):8681–8686CrossRefPubMedPubMedCentral
36.
Zhuo C, Li Q, Wu Y, Li Y, Nie J, Li D, Peng J, Lian P, Li B, Cai G, Li X, Cai S (2015) LINE-1 hypomethylation in normal colon mucosa is associated with poor survival in Chinese patients with sporadic colon cancer. Oncotarget 6(27):23820–23836CrossRefPubMedPubMedCentral
37.
The Cancer Genome Atlas, N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337CrossRef
38.
Hinoue T, Weisenberger DJ, Lange CPE, Shen H, Byun HM, van den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, Tollenaar RAEM, Laird PW (2012) Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 22(2):271–282CrossRefPubMedPubMedCentral
Metadata
Title
Meta-analysis of the prognostic value of CpG island methylator phenotype in rectal cancer
Authors
R. F. Kokelaar
H. Jones
J. Beynon
M. E. Evans
D. A. Harris
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
International Journal of Colorectal Disease / Issue 8/2018
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-018-3108-5

Other articles of this Issue 8/2018

International Journal of Colorectal Disease 8/2018 Go to the issue

Original Article

Risk factors of recurrence in T1 colorectal cancers treated by endoscopic resection alone or surgical resection with lymph node dissection

Original Article

Real-world study of a novel prognostic scoring system: for a more precise prognostication and better clinical treatment guidance in stages II and III colon cancer

Original Article

The gentamicin-collagen implant and the risk of distant metastases of rectal cancer following short-course radiotherapy and curative resection: the long-term outcomes of a randomized study

Correction

Correction to: Development of a new risk nomogram of perioperative major adverse cardiac events for Chinese patients undergoing colorectal carcinoma surgery

Short Communication

Macroscopic serosal invasion and small tumor size as independent prognostic factors in stage IIA colon cancer

Original Article

Perioperative radiotherapy is an independent risk factor for major LARS: a cross-sectional observational study